Literature DB >> 17603843

Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.

Shree R Singh1, Vida A Dennis, Christina L Carter, Shreekumar R Pillai, Eddie G Moore.   

Abstract

We have developed and evaluated an immunodominant respiratory syncytial virus (RSV) F antigen in a mouse model. The antigenic region corresponding to amino acids 255-278 of the RSV F protein was cloned into a vector containing the ctxA(2)B gene of cholera toxin (CT). The recombinant protein was expressed in Escherichia coli and analyzed on sodium dodecyl sulfate-polyacrylamide gels. The purified protein was evaluated by immunoblot and ganglioside GM(1) enzyme-linked immunosorbent assay to confirm the expression of the RSV F protein and to correct association of the recombinant protein to form a holotoxin-like chimera, respectively. We hypothesized that genetic fusion of modified CT-based adjuvant with RSV F immunodominant epitopes (rRF-255) would induce protective humoral and cellular immune responses in mice. Intranasal immunization of mice with rRF-255 overall induced higher concentrations of anti-RSV F-specific antibodies in both serum and saliva as compared with mice immunized intranasally with RSV or phosphate-buffered saline (PBS). Antibody isotype analysis (IgA, IgG1, IgG2a, and IgG2b) was also performed. The predominant IgG2a antibody isotype response in combination with cytokine analysis of helper T cell type 1 (interferon-gamma, interleukin [IL]-2, IL-12 p70, and tumor necrosis factor-alpha) and helper T cell type 2 (IL-4 and IL-10) responses revealed that rRF-255 antigen induces a prominent helper T cell type 1 immune response in mice. The rRF-255 antigen also induced serum neutralizing antibodies in immunized mice. Analysis of RSV load in lungs showed that rRF-255 immunization provided significant protection compared with PBS control animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17603843     DOI: 10.1089/vim.2007.0008

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  5 in total

Review 1.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

2.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

3.  Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine.

Authors:  Anja Krause; Yaqin Xu; Sara Ross; Wendy Wu; Ju Joh; Stefan Worgall
Journal:  Virol J       Date:  2011-07-29       Impact factor: 4.099

4.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30

5.  Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.

Authors:  Crystal Passmore; Paul E Makidon; Jessica J O'Konek; Joseph A Zahn; Jessie Pannu; Tarek Hamouda; Vira Bitko; Andrzej Myc; Nicolas W Lukacs; Ali Fattom; James R Baker
Journal:  Hum Vaccin Immunother       Date:  2013-12-10       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.